About RNA Diagnostics

This author has not yet filled in any details.
So far RNA Diagnostics has created 61 blog entries.

New test developed in Sudbury promising for cancer patients – CBC Morning North (radio)

A clinical trial taking place in Sudbury could one day help doctors around the world determine if chemotherapy is the best treatment for cancer patients. We heard more about the trial from Dr. Amadeo Parissenti. Listen (runs 8:40)

By |January 8th, 2014|Uncategorized|0 Comments

Une équipe de Sudbury derrière ce test qui prédit les taux de survie au cancer – Radio-Canada

Une équipe de Sudbury derrière ce test qui prédit les taux de survie au cancer. Listen

By |January 8th, 2014|Uncategorized|0 Comments

Sudbury cancer test predicts breast cancer survivability

SUDBURY, Ontario – A test developed in Sudbury is proving successful in predicting which breast cancer patients will best respond to chemotherapy and live cancer-free for a longer period of time following treatment.

Results conducted into the RNA Disruption Assay™ (RDA™) test were presented last month […]

By |January 7th, 2014|Uncategorized|0 Comments

New research shows RDA™ is an excellent predictor of breast cancer chemotherapy outcome

TORONTO, Ontario – Research presented at the San Antonio Breast Cancer Symposium (SABCS) demonstrated that the RNA Disruption Assay™ (RDA™) can be highly useful in guiding chemotherapy treatment for women with breast cancer.

Dr. Amadeo Parissenti, Professor, Laurentian University and colleagues presented, “High tumor RNA disruption […]

By |December 12th, 2013|Uncategorized|0 Comments

Rna Diagnostics to present at San Antonio Breast Cancer Symposium (SABCS)

TORONTO, Ontario
Dr. Amadeo Parissenti, Rna Diagnostics’ Chief Scientific Officer, will present a poster entitled, “High tumor RNA disruption is associated with increased survival in patients with locally advanced breast cancer”, at theSABCS taking place in San Antonio, Texas from December 10-14. The poster session is […]

By |October 22nd, 2013|Uncategorized|0 Comments

The goal is to stop cancer – The Portico, University of Guelph

Treating pets with cancer is our first goal but studying the disease in animals benefits humans too.
Read more

By |July 4th, 2013|Uncategorized|0 Comments

Diagnostic tool tested – Sudbury Star

A Sudbury cancer diagnostics company has been chosen for a new pilot project for emerging health-care technologies in Ontario.Rna Diagnostics, Inc. is one of three companies selected for the MaRS Excellence in Clinical Innovation and Technology Evaluation project. Read more

By |June 4th, 2013|Uncategorized|0 Comments

Rna Diagnostics selected to participate in EXCITE program to evaluate RDA™ – Life Sciences Ontario

Rna Diagnostics, Inc. (RnaDx) has been accepted into the MaRS Excellence in Clinical Innovation and Technology Evaluation (EXCITE) program for the clinical evaluation of their diagnostic test, RNA Disruption Assay™ (RDA™),and its impact on patient care for individuals undergoing breast cancer chemotherapy. Through EXCITE, The […]

By |June 3rd, 2013|Uncategorized|0 Comments

Rna Diagnostics Chosen for Ontario Clinical Testing Program – GenomeWeb Daily News

NEW YORK (GenomeWeb News) – Canadian molecular diagnostics company Rna Diagnostics has been chosen to have its breast cancer assay evaluated by the Toronto Health Economics and Technology Assessment initiative in a multi-center clinical trial, the company said on Thursday. GenomeWeb Daily News

By |May 31st, 2013|Uncategorized|0 Comments

Breakthrough health technologies to reach patients faster through MaRS EXCITE – MaRS website

The Excellence in Clinical Innovation and Technology Evaluation (EXCITE) initiative helps companies accelerate the adoption and reimbursement of innovative health technologies through a single, harmonized, pre-market, evidence-based process.

EXCITE has selected ApneaDx Inc., Medtronic of Canada Ltd. and Rna Diagnostics Inc. as the program’s initial participants.


By |May 31st, 2013|Uncategorized|0 Comments